Blood Cancer Journal

Article	Citations
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy	1601
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma	140
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	133
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience	129
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review	128
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	122
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma	117
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	112
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation	105
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib	103
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	99
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	99
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy	96
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review	92
Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy	91
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study	91
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma	77
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	76
MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma	74
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence	72
Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia	71
Genomic landscape of hyperleukocytic acute myeloid leukemia	71
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	68
B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation	63
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas	63

Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)	63
Sensitive multiple myeloma disease monitoring by mass spectrometry	61
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	61
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT	61
Clinical features and outcomes in primary nervous system histiocytic neoplasms	61
Genetically determined telomere length and multiple myeloma risk and outcome	60
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement	58
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia	57
Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning	56
Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma	53
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms	53
Disparities in time to treatment with oral antimyeloma medications	52
Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience	48
Cost comparison of post-remission strategies in younger and older AML patients in France	48
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	46
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach	46
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries	45
Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients	43
Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents	42
Large differencies in age-specific survival in multiple myeloma in the nordic countries	42
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML	41
Author Correction: Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria	39
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	39
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels	38
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia	38
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmac	38
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib	38
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib	38
A multiparametric niche-like drug screening platform in acute myeloid leukemia	37
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab	37
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score	36
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients	36
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party	36
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)	36
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	36
Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital	35
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis	35
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies	34
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity a	34
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	33
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?	32
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse	32
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms	32
Update on the management of relapsed/refractory chronic lymphocytic leukemia	31
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy	31
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome	30
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies	30
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	30
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	29
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in t	29

Asciminib in chronic myeloid leukemia: many questions still remain to be answered	29
Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study	29
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	28
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients	28
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	28
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19	28
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation	28
Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis	27
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia	27
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms	27
Time independent factors that predict relapse in adults with acute myeloid leukemia	27
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	27
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis	26
Survival trends in hematological malignancies in the Nordic countries through 50 years	26
Zanubrutinib: past, present, and future	25
Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma	25
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma	25
A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease	25
Correction: Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection	24
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies	24
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	24
Molecular monitoring in CML—a modern example of an old proverb	24
The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders	23
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia	23
Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases	23
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements	23
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	23
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy	22
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis	22
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins	22
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome	22
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia	22
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia	22
In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms	21
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development	21
The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transp	21
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen	21
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial	21
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy	20
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	20
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma	20
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	20
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	20
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy	20
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression	19
Comprehensive Review of AL amyloidosis: some practical recommendations	19
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	19
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm	19
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells	19
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity	19
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	19
Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT	19
Global burden of hematologic malignancies and evolution patterns over the past 30 years	18
Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index	18
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia	18
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia	18
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors	18
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy	18
Outcomes and prognostic factors in patients with Burkitt lymphoma/leukemia in adolescents and adults: an experience from hematology cancer consortium	17
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications	17
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping	17
Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution	17
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study	17
Global disparities in patients with multiple myeloma: a rapid evidence assessment	17
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome	17
Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis	17
Impact of COVID-19 in patients with multiple myeloma based on a global data network	17
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression	16
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma	16
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm	16
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	16
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma	16
Queries regarding the two papers each reporting on 1000 essential thrombocythemia patients in BCJ	16
Using Mendelian Randomisation to search for modifiable risk factors influencing the development of clonal haematopoiesis	16
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study	16
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma	15
Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma	15
Racial disparities in multiple myeloma and access to stem cell transplantation	15
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic	15
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	15

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	15
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era	15
Detection of minimal residual disease by next generation sequencing in AL amyloidosis	15
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma	15
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”	15
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia	15
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations	15
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab	15
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia	15
Management of patients with lower-risk myelodysplastic syndromes	15
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance	15
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-	15
RSK1 dependency in FLT3-ITD acute myeloid leukemia	15
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis	14
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies	14
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	14
MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study	14
Racial disparities in patients diagnosed with light chain (AL) amyloidosis	14
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma	14
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients	13
Exercise-induced release of cardiac and skeletal muscle injury biomarkers in patients with chronic myeloid leukemia receiving TKI therapy	13
Early mortality after chemotherapy as a quality indicator—the leukemia perspective	13
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study	13
Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control	13
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies	13
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL	13
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	13
Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India	13
Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation	13
One thousand patients with essential thrombocythemia: the Mayo Clinic experience	13
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms	13
Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma	13
Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients	13
Minor GPI(-) granulocyte populations in aplastic anemia and healthy individuals derived from a few PIGA-mutated hematopoietic stem progenitor cells	13
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival	13
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison	12
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis	12
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway	12
Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia	12
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib	12
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics	12
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study	12
Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy	12
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score	12
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	12
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6	12
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia	12
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis	12
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group	12
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020	12
BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified	12